<DOC>
	<DOCNO>NCT00118794</DOCNO>
	<brief_summary>Lapdap ( chlorproguanil-dapsone ) affordable effective drug , patient glucose-6-phosphate dehydrogenase ( G6PD ) A- deficiency susceptible haemolytic effect dapsone component Lapdap ; therefore need evaluate extent risk associate use drug setting without G6PD screen might outweigh benefit malaria treatment . The investigator evaluate , operational setting , safety effectiveness Lapdap coartemether ( lumefantrine-artemether ) treatment uncomplicated malaria patient 6 month 10 year age .</brief_summary>
	<brief_title>Lapdap Coartemether Uncomplicated Malaria</brief_title>
	<detailed_description>Patients uncomplicated malaria recruit three health centre Gambia . Children age 6 month 10 year present history illness , fever recent history fever , screen ; uncomplicated malaria , positive blood smear parasite density 500 200,000 parasites/µl , monoinfection P. falciparum , pack cell volume &gt; =20 % , invite enroll study consent give , randomize receive three daily dos lapdap , six-dose course Coartem . The first dose give mother direct observation dispense nurse ; subsequent dos give home unsupervised . Children follow actively three time ; day 3 , assess adherence treatment regimen , day 14 28 , assess parasitological haematological recovery . The mother/caregiver child encourage bring child clinic child improve concerned child ’ health . On day 3 , parent/caregiver visit home ( last dose take ) order check leftover medication , ask compliance adverse reaction . A finger prick blood sample take Hb measurement haemocue field filter paper sample measurement drug concentration . The investigator employ longitudinal randomized design , whereby subsequent episode malaria treat accord original randomization . This enable well assessment cumulative effect repeat treatment anaemia tolerability . Since patient glucose-6-phosphate dehydrogenase ( G6PD ) A- deficiency susceptible haemolytic effect dapsone component Lapdap , investigator determine G6PD genotype enzymatic activity , order evaluate extent risk associate use drug setting without G6PD screen might outweigh benefit malaria treatment .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<criteria>presentation health centre febrile illness monoinfection P falciparum parasitaemia &gt; =500/microlitre fever history fever sign severe complicate malaria ( persistent vomit without dehydration , history convulsion present illness , inability sit stand , parasitaemia &gt; 200,000/ul ) severe malnutrition clinically evident concomitant disease PCV &lt; 20 % history allergy study medication residence outside study area hence difficult follow</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>uncomplicated malaria</keyword>
	<keyword>G6PD deficiency</keyword>
	<keyword>haemolytic anaemia</keyword>
	<keyword>Lapdap</keyword>
	<keyword>Artemsinin base combination treatment</keyword>
	<keyword>compliance</keyword>
	<keyword>pragmatic trial</keyword>
</DOC>